6,307 Shares of Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,307 shares of the biopharmaceutical company’s stock, valued at approximately $1,602,000.

A number of other institutional investors have also recently made changes to their positions in the business. Toth Financial Advisory Corp purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $25,000. Burkett Financial Services LLC acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $37,000. CoreCap Advisors LLC boosted its position in Alnylam Pharmaceuticals by 744.4% in the 3rd quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 134 shares during the period. Keating Financial Advisory Services Inc. purchased a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $42,000. Finally, Root Financial Partners LLC purchased a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $48,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the sale, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 3.2%

Shares of NASDAQ:ALNY opened at $151.64 on Wednesday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $149.18 and a fifty-two week high of $479.79. The firm’s 50 day moving average price is $225.18 and its 200 day moving average price is $278.96. The company has a quick ratio of 2.43, a current ratio of 2.48 and a debt-to-equity ratio of 0.18. The stock has a market cap of $20.31 billion, a price-to-earnings ratio of 7.87 and a beta of 0.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping the consensus estimate of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the previous year, the business posted $2.90 EPS. The firm’s revenue was up 16.7% on a year-over-year basis. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. JPMorgan Chase & Co. dropped their price target on shares of Alnylam Pharmaceuticals from $375.00 to $369.00 and set an “overweight” rating for the company in a research note on Wednesday, September 30th. Royal Bank Of Canada decreased their target price on Alnylam Pharmaceuticals from $345.00 to $280.00 and set an “outperform” rating for the company in a report on Friday, October 30th. Chardan Capital decreased their target price on Alnylam Pharmaceuticals from $425.00 to $375.00 and set a “buy” rating for the company in a report on Friday, October 30th. Morgan Stanley lowered their target price on Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating for the company in a research note on Friday, October 30th. Finally, HC Wainwright restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $305.86.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.